Zydus & CMS enter pact for Desidustat in Greater China

The agreement is for Desidustat, a novel oral HIF-PH inhibitor for the treatment of anemia in patients with Chronic Kidney Disease (CKD) not-on-dialysis and for the treatment of anemia CKD patients on dialysis in Greater China, Zydus said in a statement. "Under the license agreement, CMS will pay Zydus an initial upfront payment," it added.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news

Related Links:

AbstractBackgroundThough anemia is a sign of poor renal prognosis in chronic kidney disease (CKD), hemoglobin (Hb) levels are typically higher in autosomal dominant polycystic kidney disease (ADPKD) than in other kidney diseases, and anemia has not been examined as a potential prognosticator. Thus, we investigated anemia as a factor for renal prognosis in ADPKD.MethodsIn total, 115 non-dialysis patients, 48 men and 67 women, with ADPKD were evaluated. The renal outcome of a 50% reduction in the estimated glomerular filtration rate or renal replacement therapy was examined using the Cox regression analysis and Kaplan &ndash...
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
Conclusion Long-acting erythropoiesis-stimulating agents were correlated with higher haemoglobin levels and may be more useful for patients with a low left ventricular mass index at the initiation of haemodialysis.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
Abstract Serum soluble Fas levels (sFas) is associated to erythropoietin (Epo) hyporesponsiveness in patients with chronic kidney disease (CKD). If sFas could predict the need for erythropoiesis-stimulating agents (ESA) usage and influence in erythropoiesis remains unclear. We evaluated the relation between sFas and ESA therapy in CKD patients with anemia and its effect on erythropoiesis in vitro. First, we performed a retrospective cohort study with 77 anemic patients with non-dialysis CKD. We performed in vitro studies to investigate whether sFas could interfere with the behavior of hematopoietic stem cells (HSC...
Source: American Journal of Physiology. Renal Physiology - Category: Physiology Authors: Tags: Am J Physiol Renal Physiol Source Type: research
The objectives of the conservative treatment for chronic kidney disease are to slow down the progression of kidney dysfunction, treat complications (anemia, bone diseases, cardiovascular diseases), vaccination for hepatitis B, and preparation for kidney replacement therapy.
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
A 34 year-old female with Stage V chronic kidney disease secondary to a history of sickle cell anemia and focal segmental glomerulosclerosis and on peritoneal dialysis presented to our hospital for imaging as part of routine evaluation for renal transplant. Upon receiving an MRI of the abdomen to evaluate liver architecture and kidney anatomy, a 6.6 cm left perinephric mass was incidentally found inferomedial to the left kidney and extending caudally (Figure 1). The renal parenchyma and ureter were uninvolved.
Source: Urology - Category: Urology & Nephrology Authors: Tags: Grand Rounds Source Type: research
Abstract INTRODUCTION: Severe uncontrolled secondary hyperparathyroidism and kidney transplantation history are both risk factors for fractures in hemodialyzed patients. Moreover, patients who return to dialysis after transplant failure have more severe infections/anemia and higher mortality risk than transplant-naive patients starting dialysis with native kidneys. In this context, our aim was to test the hypothesis that transplant failure patients have more secondary hyperparathyroidism than transplant-naive patients. METHODS: We retrospectively compared 29 transplant failure patients to 58 transpl...
Source: Nephrologie and Therapeutique - Category: Urology & Nephrology Authors: Tags: Nephrol Ther Source Type: research
ConclusionSofosbuvir-based regimens are effective to treat HCV in patients with CKD. In patients with mild CKD this type of therapy seems to be safe.
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
CONCLUSION: Sofosbuvir-based regimens are effective to treat HCV in patients with CKD. In patients with mild CKD this type of therapy seems to be safe. PMID: 31760038 [PubMed - as supplied by publisher]
Source: Braz J Infect Dis - Category: Infectious Diseases Authors: Tags: Braz J Infect Dis Source Type: research
Following publication of the original article [1], the authors reported errors in the presentation of Tables 2, 4 and 5.
Source: BMC Nephrology - Category: Urology & Nephrology Authors: Tags: Correction Source Type: research
This study aimed to determine the prevalence of anemia and its associated factors among CKD patients at the University of Gondar hospital, Northwest Ethiopia. Methods: A hospital-based cross-sectional study was conducted from May 1, to September 30, 2018. Consecutive sampling was used to recruit 251 study subjects. Patients were interviewed to obtain demographic data, and the patients' medical records were reviewed to obtain information on relevant medical history and laboratory parameters. Data was analyzed using SPSS version 20. Bivariate and multivariate logistic regression analyses were used to identify independent...
Source: International Journal of Nephrology and Renovascular Disease - Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
More News: Anemia | Biotechnology | China Health | Chronic Kidney Disease | Dialysis | Pharmaceuticals | Urology & Nephrology